Business
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA. 44th Annual J.P. Morgan Healthcare Conference Format: Presentation and one-on-one investor meetings Date: January 15, 202
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Corbus Pharmaceuticals Holdings, Inc.","displaySize":"","headline":null,"caption":"Corbus Pharmaceuticals Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z7Iu.c3o3K9KWXFezgFH1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18","width":300,"height":169}},"lazy":false},{"type":"text","content":"NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.","length":378,"tagName":"p"},{"type":"text","content":"44th Annual J.P. Morgan Healthcare Conference Format: Presentation and one-on-one investor meetings Date: January 15, 2026 Presentation Time 8:15 a.m. PST/11:15am ESTWebcast Link: Click Here","length":194,"tagName":"p"},{"type":"text","content":"About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.","length":818,"tagName":"p"},{"type":"text","content":"INVESTOR CONTACTS:Sean MoranChief Financial OfficerCorbus [email protected]","length":100,"tagName":"p"},{"type":"text","content":"Dan FerryManaging DirectorLifeSci Advisors, [email protected]","length":76,"tagName":"p...